Executive Director, Asset Strategy Leadership
Leads strategic positioning of clinical assets in oncology and immunology, leveraging AI-driven insights from the Recursion OS to inform go/no-go decisions, competitive differentiation, and portfolio prioritization. Works cross-functionally with clinical, platform, and business development teams to align resource allocation and advance transformative medicines. Focuses on integrating mechanistic, biomarker, and market data to build compelling narratives for internal and external stakeholders.